Arno Therapeutics, Inc. (OTC BB: ARNI)

Arno Therapeutics, Inc. (OTC BB: ARNI), a clinical-stage biopharmaceutical company, is focused on developing and commercializing innovative products designed to treat cancer patients. AR-67, a novel third-generation camptothecin analogue in Phase I studies, is the company’s lead compound. AR-67 has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. For further information, visit the Company’s web site at www.arnothera.com.